Transaction DateRecipientSharesTypePriceValue
16th December 2020William Grossman2,117Open or private sale$31.35$66,367.95
2nd October 2020William Grossman100,000Grant/award etc.$0.00
31st July 2020William Grossman100Open or private purchase$19.77$1,977.00
31st July 2020William Grossman100Open or private purchase$19.68$1,967.56
4th June 2020William Grossman55,000Grant/award etc.$0.00
29th May 2020Shane Ward107Payment by withholding$7.63$816.41
17th March 2020Richard A. Fair5,000Open or private purchase$4.00$19,998.50
3rd January 2020Rosemary Y. Williams781Exercise of derivative$0.00
3rd January 2020Alan K. Smith1,563Exercise of derivative$0.00
3rd January 2020Rosemary Y. Williams295Payment by withholding$1.40$413.00
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Bellicum Pharmaceuticals, Inc. focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. It uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.

Ticker: BLCM
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1358403
Employees: 107
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $66 M (0%)
Assets, Current: $68 M (-39%)
Property, Plant and Equipment, Net: $2 M (-36%)
Other Assets, Noncurrent: $341 Th (-58%)
Assets: $72 M (-37%)
Long-term Debt, Current Maturities: $6 M (-41%)
Accounts Payable, Current: $2 M (-5%)
Accrued Liabilities, Current: $7 M (-27%)
Liabilities, Current: $79 M (-16%)
Long-term Debt, Excluding Current Maturities: $21 M (-19%)
Liabilities: $100 M (-17%)
Common Stock, Value, Issued: $51 Th (-89%)
Common Stock, Shares, Issued: $5 M (1%)
Additional Paid in Capital, Common Stock: $515 M (0%)
Retained Earnings (Accumulated Deficit): $559 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $389 Th (18%)
Treasury Stock, Value: $51 Th (0%)
Treasury Stock, Shares: $677 Th (0%)
Stockholders' Equity (Parent): $49 M (0%)
Liabilities and Equity: $72 M (-37%)
Research and Development: $12 M (-47%)
General and Administrative Expenses: $4 M (-52%)
Operating Income/Loss: $12 M (-55%)
Other Income, net: $31 M (4041%)